Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of…
- New data include update from the fourth patient treated in the Phase 1/2 trial - Repeat topical KB105 dosing continues to be well tolerated with no adverse events or evidence of immune response PITTSBURGH, July 01, 2021 (GLOBE…